| answer text |
<p>The Advance Market Commitment (AMC) for Pneumococcal Vaccines is a dynamic financing
instrument of Gavi, the Vaccine Alliance. Its objective is to reduce deaths from severe
pneumonia by reducing the cost of the pneumococcal vaccine. The AMC does this by incentivising
vaccine manufacturers and generating greater competition by encouraging additional
manufacturers to the market. So far, 114 million children have been vaccinated with
AMC-supported pneumococcal vaccines, saving 762,000 lives.</p><p> </p><p>DFID has
committed $485 million to AMC from 2010 until 2020. The AMC has consistently delivered
and performs very strongly. It scored an A+ in its last Annual Review. The current
end date is scheduled for December 2020. DFID are currently reviewing vaccine demand
projections and in discussions with other stakeholders whether an extension is required
in order to attract new manufacturers and generate wider benefits. This review is
in line with our approach to maximise effectiveness and ensure good value for money.</p>
|
|
